Background Numerous clinical trials and observational studies have investigated various
pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19) …

Rapid reperfusion of the infarct-related artery is the cornerstone of therapy for the
management of acute ST-elevation myocardial infarction (STEMI). Canada's geography …

Background Alteplase is the standard agent used in early reperfusion therapy, but
alternative thrombolytic agents are needed. The efficacy and safety of reteplase as …

Drug delivery by nanocarriers (NCs) has long been stymied by dominant liver uptake and
limited target organ deposition, even when NCs are targeted using affinity moieties. Here we …

An acute coronary syndrome (ACS) is caused by coronary plaque rupture/erosion and
thrombus formation leading to obstruction of blood flow and distal myocardial ischemia. 1, 2 …

Thrombosis is a global health issue and one of the leading factors of death. However, its
diagnosis has been limited to the late stages, and its therapeutic window is too narrow to …

BACKGROUND: Reteplase is a more affordable new-generation thrombolytic with a
prolonged half-life. We aimed to determine the safety dose range of reteplase for patients …

Thrombus formed in blood vessel is a progressive process, which would lead to life-
threatening thrombotic diseases such as ischemic stroke. Unlike other diseases, the …

Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic
medication for acute ischemic stroke. However, multiple recent studies comparing …

Fibrinolytic agents catalyze the conversion of the inactive proenzyme plasminogen into the
active protease plasmin, degrading fibrin within the thrombus and recanalizing occluded …